To counter the urgent threat of antimicrobial resistant infections, ILSE has partnered with PHRI (Rutgers University) to create a CARB (Combatting Antibiotic Resistant Bacteria) Accelerator (CARB-A) that addresses the critical, unmet need for comprehensive, early innovation-stage discovery programs that can advance candidates for preclinical development. The proposed CARB-A has extensive discovery and preclinical development capabilities with a highly-experienced team of scientists and businessmen whose combined expertise spans more than 400 years of antimicrobial drug development experience and advanced more than 200 compounds through pharmaceutical preclinical development, resulting in 30 clinical candidates and 12 commercial products.
The goal of the CARB-A is to identify, assemble, and shepherd a small portfolio of companies with early innovative antimicrobial products through to a pre-clinical phase. Our objective is to build a robust R&D pipeline of therapeutic leads and candidates that can be developed into great drug products. We will identify 8 (Level I funding) to 12 (Level II funding) projects during 5 years and guide them into a pre-clinical status, using a gated approach for advancing candidates during their tenure at the Accelerator. The CARB-A has identified a preliminary list of potential technologies that encompass entities with novel mechanisms of action, and host directed therapies. Each product will be vetted through a multistage process to assess effectiveness, risk, and market potential to ensure the portfolio will be balanced and diversified with the most impactful technologies. In support of this proposal, ILSE-PHRI has already engaged with multiple emerging biotechnology firms, and has an extensive network that encompasses large pharmaceutical companies (e.g., Merck, Medimmune, Astra-Zenneca), non-profit organizations (e.g., ATCC), and universities (e.g., Johns Hopkins, Duke, Rockefeller).
The anticipated outcome of this accelerator would be to have at least 4-6 pre-clinical candidates that would be ready for IND enabling studies, and in addition provide valuable insights into antimicrobial resistance and tools to benefit the broad antibiotic development community over the 5 year period.
To be associated with this accelerator please contact